Alcami Adds Solid-State Characterization Capabilities to North Carolina Laboratory
The dedicated solid-state research and development suite is designed to promote discovery of novel polymorph, salt, and cocrystal forms.
Alcami, a US-based pharmaceutical contract development and manufacturing organization (CDMO), announced the addition of a 12,000 ft² solid-state characterization laboratory to its Morrisville, NC laboratory on Sept. 22, 2022. According to a company press release, the expanded laboratory is designed to increase the company’s NC footprint and complement the company’s existing sterile and oral solid drug product development, manufacturing, and analytical capabilities for products in all phases of development.
"We look forward to supporting our clients in the discovery of novel polymorph, salt, and cocrystal forms and in the development of robust crystallization and formulation processes," said Elliott Franco, vice-president, Laboratory Operations, Alcami, in the press release. "We have the technical expertise and technologies to provide our clients with a seamless transition from initial characterization through [good manufacturing practice] manufacturing and analytical release.”
Source: Alcami
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
